Emoxypine (Mexidol)vsLemon Balm

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) has a 3-hydroxypyridine structure similar to vitamin B6 (pyridoxine). It is one of the most potent inhibitors of lipid peroxidation in brain tissue — it scavenges hydroxyl radicals and peroxyl radicals, inhibits Fe2+-induced lipid peroxidation, and may chelate transition metals. It modulates the GABA-benzodiazepine receptor complex (GABA-A), enhancing GABAergic transmission through positive allosteric modulation — possibly at a site distinct from the classical benzodiazepine binding site, explaining the lack of sedation and tolerance. It improves mitochondrial function (Complex I protection, membrane stabilization), stabilizes cell membranes (reducing fluidity changes during oxidative stress), and enhances cerebral microcirculation (possibly via nitric oxide or prostaglandin modulation). The anxiolytic mechanism may involve partial agonism or different subunit selectivity.

Lemon balm inhibits GABA-transaminase (GABA-T), the enzyme that converts GABA to succinic semialdehyde in the GABA shunt, increasing GABA availability in synaptic terminals and producing anxiolytic effects via GABA-A (alpha2, alpha3 subunits) and GABA-B receptors. Rosmarinic acid provides antioxidant effects via Nrf2 activation and anti-inflammatory effects through COX-2 and NF-kB inhibition. Lemon balm inhibits acetylcholinesterase (AChE) at the catalytic site, mildly increasing acetylcholine in the hippocampus and cortex — explaining cognitive enhancement at moderate doses via muscarinic M1 and nicotinic receptor activation. At higher doses, GABAergic effects dominate, producing sedation useful for sleep. Additional mechanisms may include 5-HT2A antagonism and muscimol-like GABA-A modulation from trace constituents.